Insufficient scRNA-seq data for expression of IKBKE at single-cell level.
Insufficient scRNA-seq data for expression of IKBKE at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 719.63 | 651 / 653 | 100% | 25.00 | 603 / 605 |
lung | 98% | 597.83 | 569 / 578 | 99% | 19.71 | 1139 / 1155 |
skin | 100% | 1056.92 | 1807 / 1809 | 96% | 15.93 | 455 / 472 |
breast | 93% | 361.39 | 425 / 459 | 98% | 17.06 | 1092 / 1118 |
stomach | 87% | 436.89 | 312 / 359 | 99% | 20.49 | 283 / 286 |
pancreas | 89% | 272.07 | 292 / 328 | 97% | 14.87 | 172 / 178 |
bladder | 86% | 490.14 | 18 / 21 | 98% | 19.75 | 493 / 504 |
intestine | 81% | 594.47 | 781 / 966 | 99% | 21.58 | 522 / 527 |
esophagus | 77% | 732.92 | 1111 / 1445 | 100% | 20.06 | 183 / 183 |
kidney | 97% | 434.63 | 86 / 89 | 76% | 7.70 | 687 / 901 |
uterus | 68% | 190.49 | 116 / 170 | 97% | 19.75 | 445 / 459 |
ovary | 64% | 140.63 | 116 / 180 | 97% | 18.28 | 416 / 430 |
prostate | 96% | 540.35 | 235 / 245 | 59% | 4.01 | 295 / 502 |
brain | 69% | 243.96 | 1812 / 2642 | 65% | 5.53 | 459 / 705 |
adrenal gland | 97% | 489.41 | 251 / 258 | 17% | 1.14 | 40 / 230 |
lymph node | 0% | 0 | 0 / 0 | 100% | 79.93 | 29 / 29 |
spleen | 100% | 1992.55 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 35.81 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.16 | 1 / 1 |
peripheral blood | 99% | 1487.08 | 924 / 929 | 0% | 0 | 0 / 0 |
adipose | 93% | 322.33 | 1115 / 1204 | 0% | 0 | 0 / 0 |
liver | 36% | 79.27 | 82 / 226 | 48% | 5.29 | 196 / 406 |
eye | 0% | 0 | 0 / 0 | 83% | 8.47 | 66 / 80 |
blood vessel | 65% | 199.89 | 869 / 1335 | 0% | 0 | 0 / 0 |
heart | 33% | 70.94 | 281 / 861 | 0% | 0 | 0 / 0 |
muscle | 1% | 2.69 | 11 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
GO_0060340 | Biological process | positive regulation of type I interferon-mediated signaling pathway |
GO_0097400 | Biological process | interleukin-17-mediated signaling pathway |
GO_0051607 | Biological process | defense response to virus |
GO_0048255 | Biological process | mRNA stabilization |
GO_0032481 | Biological process | positive regulation of type I interferon production |
GO_0006955 | Biological process | immune response |
GO_0098586 | Biological process | cellular response to virus |
GO_0060337 | Biological process | type I interferon-mediated signaling pathway |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0008630 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage |
GO_0043254 | Biological process | regulation of protein-containing complex assembly |
GO_0010467 | Biological process | gene expression |
GO_0010884 | Biological process | positive regulation of lipid storage |
GO_0035456 | Biological process | response to interferon-beta |
GO_0031966 | Cellular component | mitochondrial membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_1902554 | Cellular component | serine/threonine protein kinase complex |
GO_0005829 | Cellular component | cytosol |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0008384 | Molecular function | IkappaB kinase activity |
GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
GO_0019903 | Molecular function | protein phosphatase binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0036435 | Molecular function | K48-linked polyubiquitin modification-dependent protein binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IKBKE |
Protein name | Inhibitor of nuclear factor kappa B kinase subunit epsilon Inhibitor of nuclear factor kappa-B kinase subunit epsilon (I-kappa-B kinase epsilon) (IKK-E) (IKK-epsilon) (IkBKE) (EC 2.7.11.10) (Inducible I kappa-B kinase) (IKK-i) |
Synonyms | IKKI IKKE KIAA0151 |
Description | FUNCTION: Serine/threonine kinase that plays an essential role in regulating inflammatory responses to viral infection, through the activation of the type I IFN, NF-kappa-B and STAT signaling. Also involved in TNFA and inflammatory cytokines, like Interleukin-1, signaling. Following activation of viral RNA sensors, such as RIG-I-like receptors, associates with DDX3X and phosphorylates interferon regulatory factors (IRFs), IRF3 and IRF7, as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRF3 leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNB. In order to establish such an antiviral state, IKBKE forms several different complexes whose composition depends on the type of cell and cellular stimuli. Thus, several scaffolding molecules including IPS1/MAVS, TANK, AZI2/NAP1 or TBKBP1/SINTBAD can be recruited to the IKBKE-containing-complexes. Activated by polyubiquitination in response to TNFA and interleukin-1, regulates the NF-kappa-B signaling pathway through, at least, the phosphorylation of CYLD. Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. In addition, is also required for the induction of a subset of ISGs which displays antiviral activity, may be through the phosphorylation of STAT1 at 'Ser-708'. Phosphorylation of STAT1 at 'Ser-708' seems also to promote the assembly and DNA binding of ISGF3 (STAT1:STAT2:IRF9) complexes compared to GAF (STAT1:STAT1) complexes, in this way regulating the balance between type I and type II IFN responses. Protects cells against DNA damage-induced cell death. Also plays an important role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity. Phosphorylates AKT1. . |
Accessions | ENST00000584998.5 [Q14164-2] ENST00000578328.6 A0A075B7D5 ENST00000581977.7 [Q14164-1] Q14164 A0A075B7C7 ENST00000605726.1 ENST00000579827.6 A0A075B7B4 |